Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,605
Employees7,605
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,605
Employees7,605

BIIB Key Statistics

Market cap
18.69B
Market cap18.69B
Price-Earnings ratio
13.15
Price-Earnings ratio13.15
Dividend yield
Dividend yield
Average volume
1.20M
Average volume1.20M
High today
$133.36
High today$133.36
Low today
$127.47
Low today$127.47
Open price
$132.32
Open price$132.32
Volume
1.24M
Volume1.24M
52 Week high
$236.48
52 Week high$236.48
52 Week low
$110.04
52 Week low$110.04

BIIB News

TipRanks 1d
Biogen’s New Study on Omaveloxolone for Young FA Patients: Market Insights

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

TipRanks 5d
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer?

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...

TipRanks 5d
Biogen, Stoke Therapeutics present data from studies of zorevunersen

Biogen (BIIB) and Stoke Therapeutics (STOK) announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evalua...

Analyst ratings

49%

of 37 ratings
Buy
48.6%
Hold
48.6%
Sell
2.7%

More BIIB News

Simply Wall St 6d
Biogen Insiders Sold US$1.8m Of Shares Suggesting Hesitancy

In the last year, many Biogen Inc. ( ) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whether insiders...

Biogen Insiders Sold US$1.8m Of Shares Suggesting Hesitancy

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.